Gly31-Val235 & Ser307-Leu396 with Strep and His tag at the C-terminus
43-55kDa (Reducing)
20 mM Tris，pH 7 .5，150 mM NaCl，0 .00075% LMNG，0 .0001% CHS，0 .00025% GDN，1x Protease Inhibitor Cocktail，100μM TCEP
·6 months from date of receipt, -60 to -80 °C as supplied.
·About 3 days in 2 to 8 °C.
·Please avoid repeated freeze-thaw cycles.
1. Lv Z, He Y, Xiang Y, et al. Cryo-EM complex structure of active GPR75 with a nanobody[J]. bioRxiv, 2022: 2022.08. 18.503988.
The rising prevalence of obesity and its associated co-morbidities has become a global healthcare concern. Treating obesity clinically remains a significant challenge. GPR75, a member of the G protein-coupled receptor (GPCR) family, has emerged as a novel target for managing obesity and related metabolic disorders. Studies have demonstrated that the GPR75 signaling pathway can be inhibited by small molecules and antibodies, offering a potential therapeutic strategy for obesity. The GPR75 product may enhance the development of in silico drug discovery efforts targeting obesity and its associated co-morbidities.
1μg (R: reducing condition, N: non-reducing condition).
您现在的位置：